Adding another gene therapy to its portfolio, uniQure has entered into a licensing agreement with Apic Bio for APB-102, a one-time gene therapy for the treatment of superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS). The deal, which comprises ofUS$10 M upfront as well as US$45 M in milestone payments, grants uniQure global rights to the investigational drug which is set to enter Phase I/II trials in the second half of 2023. APB-102 complements uniQure’s own gene therapy, AMT-161, that targets toxic c9orf72 as a treatment for ALS.